Literature DB >> 11992583

Comparative analysis of two coxsackievirus B3 strains: putative influence of virus-receptor interactions on pathogenesis.

H-C Selinka1, A Wolde, A Pasch, K Klingel, J-J Schnorr, J-H Küpper, A M Lindberg, R Kandolf.   

Abstract

Strain-specific differences in the interaction of coxsackievirus B3 (CVB3) with the coxsackievirus-adenovirus receptor (CAR) and the decay-accelerating factor (DAF) co-receptor proteins were investigated using a non-haemagglutinating (CVB3) and a haemagglutinating (CVB3-HA) strain of CVB3. A panel of receptor-transfected hamster CHO cells, expressing either CAR (CHOCAR cells), DAF (CHODAF cells), or both receptor proteins (CHODC cells) were used to study the interplay of CAR and DAF receptor molecules with regard to binding and infection with CVB3 and CVB3-HA. Despite clear differences in their binding phenotypes, both virus strains were found to primarily depend on the CAR receptor protein for initialization of productive infections. Cytopathic effects induced by CVB3-HA were influenced by co-expression of DAF receptor proteins. The cardiotropic potential of both virus strains was investigated in A.BY/SnJ mice. Despite comparable virus replication of both CVB3 strains in individual myocytes, the number of infected heart muscle cells was significantly lower in CVB3-HA infected mice. Infections of pancreata correlated with myocardial infections. Together these data suggest that even small differences in virus-receptor interactions, influencing virus binding and virus spread, may have an impact on the pathogenesis of CVB-induced diseases. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992583     DOI: 10.1002/jmv.2211

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

Review 1.  Virus-receptor interactions of coxsackie B viruses and their putative influence on cardiotropism.

Authors:  Hans-Christoph Selinka; Antje Wolde; Martina Sauter; Reinhard Kandolf; Karin Klingel
Journal:  Med Microbiol Immunol       Date:  2003-08-14       Impact factor: 3.402

2.  Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors.

Authors:  Ian G Goodfellow; David J Evans; Anna M Blom; Dave Kerrigan; J Scott Miners; B Paul Morgan; O Brad Spiller
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

3.  Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line.

Authors:  Sandra Pinkert; Karin Klingel; Vanessa Lindig; Andrea Dörner; Heinz Zeichhardt; O Brad Spiller; Henry Fechner
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

4.  Characterization of a putative ancestor of coxsackievirus B5.

Authors:  Maria Gullberg; Conny Tolf; Nina Jonsson; Mick N Mulders; Carita Savolainen-Kopra; Tapani Hovi; Marc Van Ranst; Philippe Lemey; Susan Hafenstein; A Michael Lindberg
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

5.  Transcriptomic analysis reveals that coxsackievirus B3 Woodruff and GD strains use similar key genes to induce FoxO signaling pathway activation in HeLa cells.

Authors:  Mi Liu; Qian Yang; Jun Han
Journal:  Arch Virol       Date:  2021-11-13       Impact factor: 2.574

6.  Early Entry Events in Echovirus 30 Infection.

Authors:  Helena Vandesande; Mira Laajala; Tino Kantoluoto; Visa Ruokolainen; A Michael Lindberg; Varpu Marjomäki
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

7.  Interaction of decay-accelerating factor with coxsackievirus B3.

Authors:  Susan Hafenstein; Valorie D Bowman; Paul R Chipman; Carol M Bator Kelly; Feng Lin; M Edward Medof; Michael G Rossmann
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

8.  A rapid and efficient method for studies of virus interaction at the host cell surface using enteroviruses and real-time PCR.

Authors:  Nina Jonsson; Maria Gullberg; Stina Israelsson; A Michael Lindberg
Journal:  Virol J       Date:  2009-12-07       Impact factor: 4.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.